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Abstract
Background: Transcriptomic approaches are relevant for studying virus-host cell dialogues to better understand
the physiopathology of infection and the immune response at the cellular level. Pseudorabies virus (PrV), a porcine
Alphaherpesvirus, is a good model for such studies in pig. Since PrV displays a strong tropism for mucous epithelial
cells, we developed a kinetics study of PrV infection in the porcine PK15 epithelial cell line. To identify as
completely as possible, viral and cellular genes regulated during infection, we simultaneously analyzed PrV and
cellular transcriptome modifications using two microarrays i.e. a laboratory-made combined SLA/PrV microarray,
consisting of probes for all PrV genes and for porcine genes contained in the Swine Leukocyte Antigen (SLA)
complex, and the porcine generic Qiagen-NRSP8 oligonucleotide microarray. We confirmed the differential
expression of a selected set of genes by qRT-PCR and flow cytometry.
Results: An increase in the number of differentially expressed cellular genes and PrV genes especially from 4 h
post-infection (pi) was observed concomitantly with the onset of viral progeny while no early global cellular
shutoff was recorded. Many cellular genes were down-regulated from 4 h pi and their number increased until 12
h pi. UL41 transcripts encoding the virion host shutoff protein were first detected as differentially expressed at 8
h pi. The viral gene UL49.5 encoding a TAP inhibitor protein was differentially expressed as soon as 2 h pi,
indicating that viral evasion via TAP inhibition may start earlier than the cellular gene shutoff. We found that many
biological processes are altered during PrV infection. Indeed, several genes involved in the SLA class I antigenic
presentation pathway (SLA-Ia, TAP1, TAP2, PSMB8 and PSMB9), were down-regulated, thus contributing to viral
immune escape from this pathway and other genes involved in apoptosis, nucleic acid metabolism, cytoskeleton
signaling as well as interferon-mediated antiviral response were also modulated during PrV infection.
Conclusion:  Our results show that the gene expression of both PrV and porcine cells can be analyzed
simultaneously with microarrays, providing a chronology of PrV gene transcription, which has never been
described before, and a global picture of transcription with a direct temporal link between viral and host gene
expression.
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Background
In vitro analyses of host cell/pathogen interactions are
essential to unravel the mechanisms of infection and to
investigate the host response to infection. Pseudorabies
virus (PrV) belongs to the Alphaherpesvirinae subfamily as
for example the human herpes simplex virus 1 (HSV-1)
and is a well-known pig pathogen responsible for
Aujeszky's disease, causing considerable economical
losses worldwide in this species [1]. Although some coun-
tries have succeeded in eradicating Aujeszky's disease
through vaccination and health policies, the disease prev-
alence still remains variable in other countries. Young pig-
lets are more severely affected by PrV infection often
resulting in fatal encephalitis, than older infected pigs,
which can remain asymptomatic or develop mild to
severe respiratory disease symptoms associated with a
limited mortality. Indeed, PrV displays a strong tropism
for epithelial cells of the oronasal respiratory tract, which
are the first cells targeted by virions [1,2]. Abortions, still-
births or weak piglets that die within 48 h of birth are also
observed when pregnant sows are infected [1]. Moreover,
PrV can infect a broad range of vertebrates resulting in a
uniform lethality but it is generally considered as a non-
pathogenic agent for man [3]. Because PrV is easy to prop-
agate in cells of several mammalian species including
rodents and is not harmful to laboratory workers, PrV is a
highly relevant model to study the biology of alphaher-
pesviruses and their interactions with host cells in vitro [1].
In addition, its genome has been reconstructed from
sequences of six different strains (Kaplan, Becker, Rice,
Indiana-Funkhauser, NIA-3, and TNL) and 70 genes
encoding structural and non structural proteins have been
annotated [4].
Viruses have evolved strategies to evade the host immune
response. In particular, herpesviruses interfere with the
Major Histocompatibility Complex (MHC) class I antigen
presentation pathway to avoid the Cytotoxic T Lym-
phocyte (CTL) response [5]. MHC class I molecules are
expressed on almost all nucleated cells and present pep-
tides, including peptides derived from viral antigens, to
CTL, which play a critical role in the defense mechanisms
against viral infection. It has been reported that PrV infec-
tion decreases the expression of MHC class I molecules on
the cell surface [6]. This down-regulation is partly
explained by the inhibition of the ABC transporter TAP
activity, due to interactions with the viral gN protein
encoded by the UL49.5 gene [7,8]. This inhibition is inde-
pendent of the non-specific mRNA cellular shut-off pro-
duced by the virion host shut-off (vhs) protein encoded
by the UL41 gene [9]. However, mechanisms other than
TAP inhibition may be involved in avoiding the MHC
class I presentation pathway.
A precise and more complete identification of cellular and
viral genes, which are up- or down-regulated during the
time course of infection, is essential to better understand
the physiopathology of infection and to identify the mol-
ecules involved in host resistance/susceptibility mecha-
nisms. During recent years, DNA microarray technology
has proven to be a very efficient high-throughput tool to
study the gene expression profiles of infected host cells or
pathogens [10,11]. To date, three transcriptomic analyses
focused on cellular gene expression have been carried out
in non-porcine PrV infected cells [12-14]. Ray and Enquist
have compared the cellular pathways regulated by PrV
and HSV-1 during infection of rat embryonic fibroblast
cells using a rat microarray [12]. In a similar system, Bruk-
man and Enquist have explored how PrV evades the IFN-
mediated immune response [13]. Finally, Blanchard et al
have used a human microarray to characterize the impact
of PrV infection in human embryonic kidney cells (HEK-
293) [14]. These studies have identified many biological
processes and host cell genes regulated during infection.
The next step in a transcriptomic approach would be the
simultaneous analysis of viral and cellular modifications
of transcription during PrV infection [10,11] using por-
cine genomic tools. Since the pig whole genome assembly
is not yet achieved, no complete pan-genomic array exists
and only partial generic microarrays are commercially
available [15]. However, the pig MHC region referred to as
the SLA (Swine Leukocyte Antigen) complex, located on
chromosome 7, is the first region of the pig genome that
is entirely sequenced and annotated [16].
In this context, our aim was to study the dialogue between
PrV and the PK15 porcine epithelial cell line, which mim-
ics the first porcine target cells. Using two different por-
cine microarrays, we followed both the viral and cellular
transcriptome kinetics during infection. These microar-
rays were the Qiagen-NRSP8 commercial array [17] and a
microarray we constructed, referred to as SLA/PrV, which
combines probe sets specific to genes localized in the SLA
complex, genes encoding other important immunological
molecules [18] and all the PrV genes. Here, we present a
large-scale analysis of the porcine physiological pathways
regulated during viral infection with a special focus on
genes in the SLA complex together with the modifications
of the PrV transcriptome.
Results
Construction of the SLA/PrV microarray and 
complementarity with the Qiagen-NRSP8 microarray
The 1789 DNA/cDNA probes spotted on the SLA/PrV
microarray fall into four distinct probe sets: i) 420 probes
localized on a segment of chromosome 7 between the loci
PRL and PRIM2A (SSC7p1.1-q1.2), which includes the
extended-SLA region and represents 272 unique
sequences, 111 belonging to the strict SLA region betweenBMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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the loci UBD and RING1 [16]; ii) 73 probes specific to 73
genes encoding molecules involved in immunity and
localized outside the SLA region [18]; iii) 80 PrV probes
specific to the 70 viral genes (Figure 1) and iv) 1170
probes randomly chosen for data normalization from
porcine cDNA AGENAE library [19,20]. The PrV/SLA
microarray covers 72.5% of the annotated sequences of
the strict SLA region (= 111/153) [16,21].
The Qiagen-NRSP8 oligonucleotide microarray contains
13297 probes, which match 8541 unique human or
mouse RefSeq or pig annotated gene NCBI accession
numbers and 1.5% of these encode immune proteins
[17]. Only 48 of the 420 probes from the extended SLA
probe set and 41 of the 73 from the immune probe set are
present on both microarrays.
Expression of PrV genes during the time course of infection
The six time points, which were studied in this experiment
– i.e. 0, 1, 2, 4, 8 and 12 hours (h) post-infection (pi),
were chosen according to viral growth kinetics observed in
PK15 cells in our experimental conditions (Figure 2). The
expression of viral genes was detected between 2 and 12 h
pi and increased during time and most of the genes were
expressed at 8 and 12 h pi. The hierarchical clustering
(HCL) of viral gene expression levels according to all con-
ditions (time and infection status) allowed us to distin-
guish two main groups: i) mock-infection at all time
points and infection until 2 h pi ii) infection from 4 until
12 h (data not shown). With the k-means method, we
identified three transcript clusters with similar expression
profiles (Figure 3). The average expression levels for the
first cluster (29 probes) showed little variation and only
from 8 h pi. The second cluster contained 30 probes cor-
responding to genes, the expression level of which
increased from 4 h pi. The last group (21 probes) dis-
played a higher increase of expression level from 2 to 8 h
pi.
Using a linear model and student t tests, the analysis of
viral genes, which were differentially expressed between
infected and mock-infected cells at each time pi (FDR =
Map of the PrV transcriptome Figure 1
Map of the PrV transcriptome. The relative location of transcripts and designed amplicons are shown. UL and US regions 
of the PrV genome are represented in black while IR and TR regions are in pink. Transcripts corresponding to each gene are 
represented with arrows (coding region in orange and non-coding regions or introns in green). Amplicons are represented in 
blue on the genome. The name of each amplicon is written above the corresponding genome location. Size is measured in kb.
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0.05) indicated that three differentially expressed probes
were observed as soon as 1 h pi and that this number
increased drastically between 2 and 8 h (39 additional
probes) and reached a plateau after 8 h pi (Table 1). The
important increase between 4 and 8 h confirmed the HCL
and k-means results and correlated with the PrV growth
curve (Figure 2). Nineteen probes were not differentially
expressed between infected and mock-infected cells at any
time and 16 of them were found in the less variable cluster
by the k-means method (Figure 3). Most of the differen-
tially expressed probes belonged to the two most variable
clusters. Among the 58 differentially expressed probes, 26
recognized two to four transcripts and 32 were specific to
a single transcript (Table 2). When examining these latter
32 genes, the first differentially expressed genes observed
1 h pi were US1 and UL29 encoding two non structural
proteins RSP40 and ICP8, respectively, and UL49.5
encoding the virion envelope glycoprotein gN. However,
IE180 encoding the immediate early protein IEP, a trans-
activator of early gene expression was found differentially
expressed at 4 h pi. Moreover, the four genes, which were
differentially expressed between 8 and 12 h, specify non
structural (UL9), capsid (UL28), tegument (UL36) and
envelope (US8) transcripts. The differential expression of
UL41 encoding vhs protein was first detected at 8 h pi.
Among the probes recognizing two transcripts, PKNIA3
specific of US3min and US3maj involved in the inhibi-
tion of apoptosis was also differentially expressed from 8
h pi and UL37 specific of UL37min and UL37maj encod-
ing a tegument protein was differentially expressed at 12
h pi.
Global PK15 differential gene expression during the time 
course of infection
The number of differentially expressed cellular probes
increased with time in parallel to viral gene expression
(Table 1). Between 0 and 2 h pi most of the SLA/immune
probes showed no change and few differentially expressed
genes were detected from 1 h pi with the Qiagen-NRPS8
microarray (Table 1). As shown in Table 1, the SLA/PrV
microarray identified 1, 0, 2, 36, 107 and 107 differen-
tially expressed probes at 0, 1, 2, 4, 8 and 12 h pi, respec-
PrV growth kinetics in PK15 cells Figure 2
PrV growth kinetics in PK15 cells. The PK15 cells were infected with PrV NIA3 at 20 MOI in HMS-M medium. PrV was 
titrated in the medium by plaque assay at different times pi (0, 4, 8, 12, 22, 26, 32 and 50 h pi). PrV titer was expressed as 
plaque forming units per ml (pfu/ml).
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tively [see Additional file 1] and the Qiagen-NRSP8
microarray identified 31, 181, 2756, 6693 differentially
expressed probes at 1, 2, 4 and 8 h pi [see Additional file
2], respectively. The SLA/PrV microarray data show that
86 (31/36), 82 (88/107), and 87 % (93/107) of the differ-
entially expressed probes were down-regulated at 4, 8 and
12 h pi, respectively and the Qiagen-NRSP8 microarray
data show that 13 (4/31), 26 (47/181), 54 (1494/2756)
and 52 % (3509/6693) of the differentially expressed
probes explored in this case were down-regulated at 1, 2,
4 and 8 h pi, respectively (Table 1). With the k-means
method, the expression levels for each condition (time
and infection status) of the SLA/PrV differentially
expressed probes set were clustered in three groups (Figure
Clusters of PrV gene expression levels identified by the k-means method Figure 3
Clusters of PrV gene expression levels identified by the k-means method. The average of normalized intensities for 
all mock-infected conditions and for each infected condition, centered (median) by genes were analyzed with the k-means 
method (three clusters). For each cluster, one graph and one clustering picture are represented. The graph shows the mean of 
the expression levels of all genes (x = Time; y = mean of levels of expression). The clustering picture depicts the mean of each 
gene expression level for all mock-infected time points and for each infected time point (x = Time; y = level of expression). The 
list of PrV amplicons belonging to each cluster, the list of the corresponding viral genes and the location of the corresponding 
proteins in virion structure (for amplicons that hybridize to a single transcript) are represented on the right. The names of the 
probes that are differentially expressed are represented in blue. To distinguish immediate early, early and late genes, early 
genes are underlined. All other genes are late genes except IE180 which is the only immediate early gene of PrV.
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4). Eighty-eight probes with a small decrease in expression
levels from 4 h pi were found in the first cluster and 45
probes with a stronger decrease in expression levels from
2 h pi in the second cluster. The third cluster contained 27
up-regulated probes at 8 h pi. The results obtained with
both microarrays show that many cellular genes were
down-regulated during the time course of the experiment
especially between 4 and 12 h pi.
PrV infection alters multiple biological processes and 
cellular functions
For each time point, the differentially expressed genes
from the Qiagen-NRSP8 microarray were classified into
biological processes using GO terms when available
(Table 3). The biological processes that contained more
than 5% of the differentially expressed genes during the
period between 2 and 8 h pi included: protein metabo-
lism and modification (BP0060), nucleoside, nucleotide
and nucleic acid metabolism (BP00031), developmental
process (BP00193), signal transduction (BP00102), trans-
port (BP00141), cell cycle (BP00203), immunity and
defense (BP00148), intracellular protein traffic
(BP00125) and cell structure and motility (BP00285).
Several biological processes were predominantly regu-
lated 1 h pi such as developmental processes (BP00193)
and signal transduction (BP00102). Other biological
processes were regulated later such as cell adhesion
(BP00124) or apoptosis (BP00179) from 2 h pi and
homeostasis (BP00267) from 4 h pi.
The Ingenuity Pathway Analysis (IPA) of the differentially
expressed probes from the Qiagen-NRSP8 microarray
identified 82 different top functions associated with sig-
nificant networks (Table 4). Three top functions were reg-
ulated early during infection (1 h pi): gene expression,
molecular transport and drug metabolism. Sixteen, 68
and 67 top functions were modulated by PrV infection at
2, 4 and 8 h pi. Fifteen and 14 top functions were specific
of time points 4 and 8 h pi, respectively. The number of
regulated top functions strongly increased from 4 h pi.
The top functions containing the highest number of focus
genes at both 4 and 8 h pi were those involved in cancer,
cell cycle and cell signaling with the first two detected as
early as 2 h pi. Immune response and immunological dis-
ease top functions were found from 4 h pi and immune
and lymphatic system development and function at 8 h
pi. Cell death top function was first detected at 2 h pi.
PrV infection modifies the expression of genes involved in 
MHC antigenic presentation pathways
The expression of many genes belonging to the SLA class I
antigenic presentation pathway was modulated during
PrV infection according to the results of both microarrays
(Table 5). SLA Ia genes were down-regulated from 4 h pi
with the SLA/PrV microarray and from 8 h pi with the Qia-
gen-NRSP8 microarray. TAP1 and TAP2 genes, encoding
molecules involved in peptide transport from the cytosol
to the endoplasmic reticulum, were also down-regulated
8 h pi according to the results of the Qiagen-NRSP8
microarray. Surprisingly, TAP1 was up-regulated 8 h pi
with the SLA/PrV microarray. PSMB8 (alias LMP7), one of
the genes encoding immunoproteasome molecules was
up-regulated from 4 h pi on the Qiagen-NRSP8 microar-
ray.
Unexpectedly, our results show that transcript levels of
genes belonging to the MHC class II antigenic presenta-
tion pathway were also modulated during PrV infection.
Expression of SLA-DOB and SLA-DMB decreased at 4 h pi
according to the results from the SLA/PrV microarray
(Table 5). SLA-DMB was also down-regulated with the
Qiagen-NRSP8 microarray 8 h pi while SLA-DOA, SLA-
DQA1 and CIITA were up-regulated at this time point
(Table 5).
Table 1: Number of viral and cellular probes differentially expressed at each time point.
Probe set Microarray Probe subset T0 T1 T2 T4 T8 T12
PrV SLA/PrV Probes homologous to a single transcript 0 3 7 18 26 30
Total 0 3 13 34 52 58
Pig SLA/PrV up-regulated SLA/Immune probes 0 0 0 1 4 3
down regulated SLA/Immune probes 0 0 0 11 18 13
up-regulated random probes 1 0 2 4 15 11
down-regulated random probes 0 0 0 20 70 80
Total 1 0 2 36 107 107
Qiagen- NRSP8 up-regulated probes ND* 27 134 1262 3184 ND*
down-regulated probes ND* 4 47 1494 3509 ND*
Total ND* 31 181 2756 6693 ND*
*ND: not determinedBMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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Table 2: Viral probes and fold-change during infection kinetics.
Amplicon name Transcript name Fold-change Encoded protein and function* Structural role*
T0 T1 T2 T4 T8 T12
ORF1 ORF1 - - - - - unknown virion
UL54 UL52/UL53/UL54 - - - - - -
UL53 UL52/UL53 - - 4.6 6.6 6.7 7.4
UL52 UL52 - - - 4.7 6.4 5.6 DNA replication; primase subunit of UL5/
UL8/UL52complex
nonstructural
UL51 UL51 - - - - - - viral egress tegument
UL50 UL50 - - - - - - dUTPase nonstructural
UL49.5 UL49.5 - 4.4 6.4 9.0 10.4 13.5 gN; immune evasion (TAP inhibitor) envelope
UL49 UL49.5/UL49 - - - - - -
UL48 UL48 - - - - - - VP16, α-TIF; gene regulation(transactivator); 
viral egress
tegument
UL47 UL48/UL47 - - - - 4.0 3.9
UL46 UL48/UL47/UL46 - - - - - - VP11/12; unknown; tegument protein
GII UL28/UL27 - - - - 6.7 6.3
ICP18.5 UL28 - - - - - 7.4 ICP18,5; DNA cleavage and packaging; 
component of the UL15/UL28 terminase
capsid precursor
UL29 UL29 - 6.0 9.2 10.6 8.9 10.9 ICP8; DNA replication and recombination; 
binds ssDNA
nonstructural
UL30 UL30 - - 4.2 - - - DNA replication; DNA polymerase subunit of 
UL30/UL42 holoenzyme
nonstructural
UL31 UL32/UL31 - - - 4.5 9.2 10.1
UL32 UL32 - - - - 4.0 4.1 DNA packaging; efficient localization of 
capsids to replication compartments
capsid precursor
UL33 UL33 - - - - 4.5 5.8 DNA cleavage and packaging; associates with 
UL28 and UL15
nonstructural
UL34 UL33/UL34 - - - - 6.1 5.0
UL35 UL33/UL34/UL35 - - 5.6 7.1 9.5 9.5
UL361 UL36 - - - - - - VP1/2; viral egress(capsid tegumentation); 
interacts with Ul37 and capsid
tegument
UL362 UL36 - - - - - 3.8 VP1/2; viral egress(capsid tegumentation); 
interacts with Ul37 and capsid
tegument
UL37 UL37maj/UL37min - - - - - 5.0
UL38 UL38 - - - - - - VP19c; minor capsid protein; UL38/UL18/
UL18 triplex component
capsid
UL39 UL39 - - - - 4.4 6.3 nucleotide synthesis; large subunit of 
ribonucleotide reductase
nonstructural
UL40 UL39/UL40 - - - - - -
UL41 UL41 - - - - 4.2 6.8 VHS, gene regulation; Rnase, degrades host 
and viral mRNAs
tegument
UL42 UL42 - - - 6.3 6.9 4.6 DNA replication; polymerase accessory 
subunit of UL30/UL42 holoenzyme
nonstructural
UL43 UL43 - - - - 4.1 6.2 inhibits glycoprotein-mediated membrane 
fusion; type III membrane protein
envelope
GIIINIA3 UL44 - - - 8.2 12.7 13.9 gC; viral entry (virion attachment); type I 
membrane protein
envelope
ORF2NIA3 UL24/UL25/UL26/UL26.5 - - - - - -
UL26NIA3 UL24/UL25/UL26 - - - 6.7 8.3 7.6
ORF1NIA3 UL24/UL25 8.1 8.0
UL25NIA3 UL24/UL25 - - - 8.3 10.7 12.2
UL24NIA3 UL24 - - - 6.9 9.8 10.4 unknown, type III membrane protein unknown
TKNIA3 UL23 - - - - 5.0 6.8 TK, nucleotide synthesis; thymidine kinase; 
selectively activates acyclovir
nonstructural
GHNIA3 UL22 - - 4.8 6.0 8.8 9.0 gH; viral entry (fusion); cell-cell spread; type i 
membrane PT
envelope
UL21NIA3 UL21 - - - - 5.9 5.5 unknown; capsid-associated tegument 
protein; interacts with UL16
tegument
UL20NIA3 UL20 - - - 3.8 5.3 7.3 viral egress, type III membrane protein unknown
UL191 UL19maj/UL19min - - - 5.0 9.7 10.8
UL192 UL19maj/UL19min - - 6.6 8.6 12.6 12.9BMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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Immune response, apoptosis, nucleic acid binding and 
actin cytoskeleton pathways are modulated during PrV 
infection
Among all the biological processes (Table 3) and top func-
tions (Table 4), shown to be regulated during PrV infec-
tion, we examined in greater detail genes differentially
expressed in four pathways i.e. immune response, apopto-
sis, nucleic acid binding and actin cytoskeleton (Table 5).
For genes involved in immune response, we observed that
CD4 and CD69 were up- and down-regulated from 4 h pi,
respectively (Table 5) and that several chemokine ligand
and interleukin genes such as IL12A, IL12B and IL17 were
down-regulated at 4 and 8 h pi. These observations have a
poor biological significance. Since the relevant gene prod-
ucts are known to be specific of immune cells, it is proba-
ble that these transcript expressions are not correlated
UL18 Ul19min/UL18 - - - 7.0 5.7 9.6
UL15EX2 UL15 (2nd exon) - - 6.4 6.5 7.5 9.2 DNA cleavage/encapsidation; terminase 
subunit of UL15/UL28 terminase6
capsid precursor
UL17 UL17 - - - - - - DNA cleavage and encapsidation inner capsid
UL16 UL17/Ul16 - - - 4.5 6.2 5.0
UL15EX12 UL15 (1st exon) - - - - 4.0 7.7 DNA cleavage/encapsidation; terminase 
subunit of UL15/UL28 terminaseUL6
capsid precursor
UL14 UL14 6.1 6.1 9.8 unknown unknown
UL142 UL14 - - - - 6.3 7.8 unknown unknown
UL13 UL14/UL13 - - - - - -
UL12 UL14/UL13/UL12 - - - - 3.7 5.3
UL11 UL14/UL13/UL12/UL11 - - - - - 6.0
UL10 UL10 - - - - 6.6 6.1 gM; inhibits glycoprotein-mediated membrane 
fusion; type III membrane protein
envelope
UL92 UL9 - - - - - 4.1 not found non structural
UL8.5 UL9/UL8.5 - - - 4.0 - -
UL8 UL9/UL8.5/UL8 - - - - - -
UL7 UL6/UL7 - - 5.0 7.4 10.7 9.4
UL6 UL6 - - 5.0 12.7 13.8 13.3 capsid protein; portal protein; docking site for 
terminase
capsid
UL5 UL5 - - 4.3 6.3 8.7 5.9 DNA replication; part of UL5/UL8/UL52 
helicase/primase complex
nonstructural
UL4 UL5/UL4 - - - - 3.5 5.5 unknown
UL3.5 UL1/UL2/UL3/UL3.5 - - - - - -
UL3 UL1/UL2/UL3 - - - - 5.1 6.5
UL2 UL1/UL2 - - - 4.2 5.4 5.4
UL1 UL1 - - - - 6.5 7.3 gL; viral entry (fusion); sell-sell spread envelope
LLTE1 LLT (1st exon) - - - 4.6 6.5 8.0 not found unknown
EP02 EP0/LLT - - - - - -
EP01 EP0/LLT - - - - 6.3 4.7
LLTI2 LLT intron - - - - 3.7 4.7
LLTE21 LLT (2nd exon) - - - - - - not found unknown
IEP2 IE180 - - - 3.5 - - ICP4; gene regulation (transactivator); 
immediate early protein
nonstructural
IEP1 IE180 - - - - - - ICP4; gene regulation (transactivator); 
immediate early protein
nonstructural
Ba5 IE180/LLT (2nd exon) 5.9 6.7 4.3
LLTE222 LLT (2nd exon) - - - 6.8 8.9 8.2 not found unknown
RSP40 US1 - 5.3 8.3 12.9 15.3 13.0 RSP40/ICP22; unknown; HIV-1 homolog acts 
as regulator of gene expression
nonstructural
PKNIA3 US3maj/US3min - - - - 6.0 5.0 PK, minor and major form of protein kinase; 
inhibits apoptosis
tegument
GXGG US3maj/US3min/US4 - - 6.5 9.1 10.6 11.0
GP50GD US6 - - - - - - gD; viral entry, type I membrane protein envelope
GP63GI US6/US7 - - - 5.0 6.3 8.5
GIGE US8 - - - 4.0 - 4.3 gE; cell-cell spread envelope
11K2 US9/US8 - - - 9.0 10.0 10.4
28KNIA3 US2 - - - 6.2 6.9 7.1 28K, tegument protein; membrane associated 
protein
tegument
*gene function and structural role [1] are only specified for amplicons that hybridize to a single transcript.
- gene not found differentially expressed between PrV infected and mock-infected cells
Table 2: Viral probes and fold-change during infection kinetics. (Continued)BMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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with significant protein synthesis in the present epithelial
cell context. Among the genes involved in interferon-
mediated immunity, many were modulated during PrV
infection (Table 5) i.e. IFNAR2 and IFI6 transcript levels
increased from 4 h pi and ISGF3G transcript levels at 8 h
pi. The expression of IRF1, IRF2and IRF5 appeared down-
regulated from 4 h pi and that of IRF3 at 8 h pi. IFNA6,
IFI30 were down-regulated 8 h pi while IFNG, which was
included in the SLA/PrV probe set, was not detected as a
differentially expressed gene. In addition, the expression
of TLR8, involved in recognition of viral nucleic acid bind-
ing was decreased at 8 h pi. Immunophilin genes were
also regulated during infection. From 4 h pi PPIA (alias
Cyclophilin A) was down-regulated (Table 5) and at 8 h
pi PPIF and PPIG were down-regulated while PPIH was
up-regulated.
Clusters of PK15 gene expression levels identified by the k-means method Figure 4
Clusters of PK15 gene expression levels identified by the k-means method. The expression levels of genes that are 
differentially expressed between infected and mock-infected cells at each time point are analyzed by the k-means method 
(three clusters). Averages of normalized intensities for all mock-infected conditions and for each infected condition were cen-
tered (median) by genes. For each cluster, one graph and one clustering picture are represented. The graph shows the mean of 
the expression levels of all genes (x = Time; y = mean of levels of expression) and the clustering picture depicts the mean of 
each gene expression level for all mock-infected time points and for each infected time point (x = Time; y = level of expres-
sion).
T8 MI T0 T1 T4 T12 T2
I
NKAP
MYL9
SLA-7
CCT7
ZNF546
PI16
4S ribosomal protein S3
Unknown
CXCR6
HIST1H2AL
Heterogenous nuclear ribonucleoprotein
HLA-DOB
Unknown
Unknown
SRF
Unknown
Pyruvate kinase isosymes M1/M2
6S ribosomal protein L11
Unkown
Unknown
PFDN4
SLC39A7
Unknown
COX3
SPMI
Unknown
Unknown
Unknown
Ubiquitin
HSPA8
Unknown
LMD1
Unknown
SLA class 1
4S ribosomal protein S8
4S ribosomal protein S17
SLA class 1
6S ribosomal protein L19
Calcyclin
6S ribosomal protein L18
C7H6orf48
Tumor protein p73
RFHC1
Unkown
6S ribosomal protein L17
CPNE5
6S ribosomal protein L37a
4S ribosomal protein S3
Putative methyl-transferase
Unkown
13KDa leucine-rich protein
Guanine nucleotide binding protein G
NADH-ubiquinone oxidoreductase chain
RGL2
C6orf49
Unknown
SET protein
Splicing factor subunit 1
Unknown
EGD2
FKBP5
Unknown
6S ribosomal protein L11
Nucleobindin 2 precursor
C2orf178
6S ribosomal protein L13
HLA-DMB
Unknown
GSTZ1
GATA-4
NifU-like protein
Apolipoprotein 1-IV precursor
TAP1
Unknown
Eukaryotic initiation factor 4A-II
ZNF193
U4/U6 small nuclear ribonucleoprotein
LY6G6C
CWFN
HM13
Fibrinogen alpha chain
Unknown
Unknown
SLA class 1
Cyclin-dependent kinase regulatory subunit 2
KLF9
Unknown
Unknown
HIST1H4J
Unknown
Unknown
KCTD20
Unknown
Ferritin light chain
Unknown
Fibronectin
Unknown
Unknown
Unnkown
SPG7
Unknown
Unknown
Unknown
C6orf89
Unknown
PPIA
HIST1H2BK
Unknown
Unknown
COX3
HIST3H2BB
Unknown
6S ribosomal protein L19
COX2
Unknown
Unknown
COX3
Unknown
SFP57
H2AfJ
RAN
Unknown
BTNL5/BTNL6
Unknown
Calmodulin
AS16
Mitogen activated protein kinase kinase kinase 3
4S ribosomal protein S3
Unknown
Ubiquitin
YV28
PPIA
ACTB
Calpain 2 large subunit precursor
Forkhead box protein 01A
Epithelial protein lost in neoplasm
DNA-binding protein inhibitor ID-3
Pantothenate kinase 4
M3KC
Jerky protein
Guanine nucleotide exchange factor DBS
RPL10A
Tumor suppressor p53-binding protein 1
SUF1
TRIM26
Unknown
Unknown
Unknown
CED2
Unknown
CCR7
Adiponutrin
Epithelial protein lost in neoplasm
SRPK1
SPBP
APOBEC2
Unknown
Zinc phosphodiesterase ELAC protein 2
RS11
Unknown
Scale of expression levels
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I
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I
Cluster 1
T8 MI T0 T1 T4 T12 T2
I
1
0
-1
Cluster 2
T8 MI T0 T1 T4 T12 T2
I
1
0
-1
Cluster 3
T8 MI T0 T1 T4 T12 T2
I
1
0
-1
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For the apoptosis pathway, genes belonging to the BCL-2
molecule family, FAIM2, CASP1 and CASP3 were down-
regulated whereas CASP7 and NF-KB2 were up-regulated.
Transcript levels of JAK1, XBP1, ATF4 and HSPA5 were
decreased at 8 h pi. HSPA1A, HSPA1B, HSPA2, HSPA4,
HSPA4K and HSPA8 were up-regulated at 8 h pi and
EIF2A from 4 h pi. HSPA6 was first down-regulated at 2 h
pi and then up-regulated from 4 h pi. Several differentially
expressed genes, which belong to the apoptosis pathway,
were also involved in the stress response.
Among the differentially expressed genes that play a role
in nucleoside, nucleotide and nucleic acid binding, the
expression of histone genes HIST1H2AL, HIST1H4J,
HIST1H2BK was decreased from 4 h pi. Expression of sev-
eral histone deacetylases was also regulated during infec-
tion: HDAC2 and HDAC10 expression levels increased,
while HDAC3, HDAC6, and HDAC9 expression
decreased. HDAC2 and HDAC9 were regulated early from
2 h pi. Several genes encoding signal transducers and acti-
vators of transcription (STAT1, STAT3, STAT5B and
STAT6) were down-regulated during PrV infection.
Within the actin cytoskeleton pathway, ACTG1 was up-
regulated very early i.e. as soon as 1 h pi. Other genes such
as ACTC1, ACTRT2, ACTA4, MYO1D and MYO5A were all
down-regulated from 4 or 8 h pi and ACTL6A was up-reg-
ulated at 8 h pi.
Validation of microarray results by quantitative real-time 
PCR (qRT-PCR)
Five genes involved in the presentation antigen class I
pathway were studied by qRT-PCR: SLA Ia, TAP1, TAP2,
PSMB8 and PSMB9. PPIA, down-regulated during infec-
Table 3: Biological processes associated with differentially expressed cellular genes.
Biological process* Time pi (h)§
T1 T2 T4 T8
Protein metabolism and modification (BP00060) 1 26 311 768
Nucleoside, nucleotide and nucleic acid metabolism (BP00031) 3 22 321 702
Developmental processes (BP00193) 8 16 224 487
Signal transduction (BP00102) 5 14 337 737
Transport (BP00141) 1 13 139 308
Cell cycle (BP00203) 2 12 124 262
Immunity and defense (BP00148) 1 11 120 309
Intracellular protein traffic (BP00125) 2 10 115 266
Cell structure and motility (BP00285) 2 7 119 279
Cell proliferation and differentiation (BP00224) 2 6 100 215
Other metabolism (BP00289) 2 6 71 159
Apoptosis (BP00179) 0 6 61 132
Cell adhesion (BP00124) 0 5 68 136
Carbohydrate metabolism (BP00001) 0 3 67 165
Amino acid metabolism (BP00013) 1 3 36 70
Protein targeting and localization (BP00137) 1 3 25 65
Blood circulation and gas exchange (BP00209) 0 3 9 26
Oncogenesis (BP00281) 0 2 57 116
Neuronal activities (BP00166) 1 2 50 106
Lipid, fatty acid and steroid metabolism (BP00019) 0 1 71 183
Electron transport (BP00076) 0 1 32 69
Muscle contraction (BP00173) 0 1 26 55
Sensory perception (BP00182) 0 1 25 60
Coenzyme and prosthetic group metabolism (BP00081) 0 1 19 46
Miscellaneous (BP00211) 0 1 12 30
Phosphate metabolism (BP00095) 0 1 8 27
Sulfur metabolism (BP00101) 0 1 8 22
Nitrogen metabolism (BP00090) 0 1 5 5
Non-vertebrate process (BP00301) 0 0 1 3
Homeostasis (BP00267) 0 0 16 49
Biological process unclassified (BP00216) 7 40 549 1232
Number of analyzed genes 24 141 1272 4458
§ The number of genes from the Qiagen_NRSP8 microarray found in Panther database is reported at each time point for each biological process.
*The same focus gene may exist in different biological processes.BMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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Table 4: Top functions associated with significant networks identified by IPA and number of focus genes at each time point.
Top functions Time
T1 T2 T4 T8
Gene Expression 9 12 178 297
Molecular Transport 9 - 81 372
Drug Metabolism 9 - 31 83
Cancer - 47 386 357
Connective Tissue Development and Function - 27 103 152
Cell Cycle - 24 246 432
Cellular Development - 23 144 64
Cell Death - 23 141 205
Cell Morphology - 23 91 58
Cellular Movement - 15 92 125
Cellular Assembly and Organization - 15 82 358
Post-Translational Modification - 13 75 79
Small Molecule Biochemistry - 13 64 324
Amino Acid Metabolism - 13 56 219
Neurological Disease - 12 59 147
Organismal Injury and Abnormalities - 12 30 56
Cellular Growth and Proliferation - 11 93 114
Connective Tissue Disorders - 11 15 21
Cell Signaling - - 223 662
DNA Replication Recombination and Repair - - 183 194
Genetic Disorder - - 128 218
Nervous System Development and Function - - 98 166
Hematological Disease - - 92 89
Protein Synthesis - - 88 204
Dermatological Diseases and Conditions - - 82 175
Hematological System Development and Function - - 81 116
Lipid Metabolism - - 79 363
Cell-To-Cell Signaling and Interaction - - 76 122
Skeletal and Muscular Disorders - - 76 33
Immune Response - - 71 246
Cardiovascular Disease - - 70 80
Cellular Function and Maintenance - - 61 263
Embryonic Development - - 54 180
Endocrine System Development and Function - - 53 62
Immunological Disease - - 44 54
RNA Post-Transcriptional Modification - - 43 122
Nucleic Acid Metabolism - - 39 130
Reproductive System Development and Function - - 35 26
Tissue Development - - 34 73
Protein Trafficking - - 34 63
Protein Folding - - 32 31
Carbohydrate Metabolism - - 31 136
Cardiovascular System Development and Function - - 31 127
Organismal Development - - 29 30
Cellular Compromise - - 28 96
Organ Morphology - - 28 91
Vitamin and Mineral Metabolism - - 27 61
Skeletal and Muscular System Development and Function - - 25 33
Developmental Disorder - - 18 33
Inflammatory Disease - - 16 95
Nutritional Disease - - 16 30
Infectious Disease - - 14 65
Metabolic Disease - - 12 89
Viral Function - - 61 -
Reproductive System Disease - - 48 -
Ophthalmic Disease - - 32 -BMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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tion, and TNF, even if not detected as differentially
expressed in our transcriptome experiment, were also cho-
sen for validation (Table 6). qRT-PCR were performed for
a subset of conditions at 0, 2, 4, 8, and 12 h pi (see mate-
rials and methods). We confirmed that SLA Ia genes were
down-regulated during infection from 8 h pi. We also
observed a clear down-regulation of TAP1 and TAP2 from
8 and 4 h pi, respectively. An early down-regulation of
PSMB8 and PSMB9 was detected before 2 h pi. TNF was
strongly up-regulated from 4 h pi and PPIA was down-reg-
ulated from 2 h pi.
Cell surface expression of MHC class I and MHC class II 
molecules on PK15 cells during PrV infection
Since our experiments, as well as other studies [6,7], have
clearly indicated a down-regulation of the MHC class I
genes during PrV infection, we checked, by flow cytome-
try, for a down-regulation of surface MHC class I mole-
cules on PrV infected PK15 cells at 8 h pi. To visualize
infected cells, we used, in the same experimental condi-
tions, a recombinant PrV strain (derived from NIA3)
expressing the green fluorescent protein (GFP). Ninety
percent of the cells appeared infected and 73% of these
infected cells expressed surface MHC class I molecules on
their surface while 89.1% and 83.9% of the mock-infected
cells expressed MHC class I molecules at 0 and 8 h pi,
respectively (data not shown). The MHC class I mean flu-
orescence intensity of infected cells at 8 h pi was 50.9% of
that of mock-infected cells (mean of three experiments)
thus confirming a clear decrease of MHC class I molecules
expression on the surface of infected cells (Figure 5). As a
control, we observed that the expression of tubulin,
detected by Western blot, remains unchanged even 8 h pi
in PK15 cells (data not shown).
Since a significant variation in MHC class II transcript lev-
els during infection was detected in our transcriptome
analysis, we also analyzed the expression of MHC class II
molecules on the surface of PK15 cells. Our results show
that 5.5% of mock-infected cells (at 0 and 8 h pi) and
infected cells (0 h pi) expressed surface MHC class II mol-
ecules. However, we could not detect any differential
expression between infected and mock-infected cells at 8
h pi.
Discussion
A joint PrV-porcine epithelial cell transcriptomic approach
This work is the first study of PrV transcriptome expres-
sion during the time course of infection. Moreover, it is
the first time that the gene expressions of both PrV (NIA3
strain) and porcine cells during infection are analyzed
simultaneously and we demonstrate that virus and host 
Hair and Skin Development and Function - - 31 -
Organ Development - - 31 -
Cardiac Fibrosis - - 30 -
Viral Infection - - 30 -
Cardiac Enlargement - - 28 -
DNA Replication - - 20 -
Cardiac Pulmonary Embolism - - 17 -
Dermatological Diseases and Condition - - 17 -
Cardiac Necrosis/Cell Death - - 16 -
Digestive System Development and Function - - 16 -
Hepatic System Disease - - 14 -
Tumor Morphology - - 13 -
Protein Degradation - - - 119
Energy Production - - - 84
Gastrointestinal Disease - - - 65
Behavior - - - 61
Immune and Lymphatic System Development and Function - - - 61
Renal Necrosis/Cell Death - - - 33
Renal and Urological System Development and Function - - - 32
Endocrine System Disorders - - - 31
Cardiac Hypertrophy - - - 30
Organismal Survival - - - 28
Free Radical Scavenging - - - 27
Respiratory System Development and Function - - - 25
Tissue Morphology - - - 23
Hepatic System Development and Function - - - 21
Focus genes 12 98 1474 2887
*The same focus gene may exist in different top functions.
§ The number of focus genes from the Qiagen_NRSP8 microarray is reported at each time point for each top function.
Table 4: Top functions associated with significant networks identified by IPA and number of focus genes at each time point. (Continued)BMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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Table 5: Subset of differentially expressed cellular genes at each time point.
Pathway or function Clone or oligo name Gene symbol Human refseq Fold change Microarray
T0 T1 T2 T4 T8 T12
Class I antigenic Pathway SS00013127 HLA-A NM_002116 NS - - - -4.6 NS Qiagen-NRSP8
SS00001303 HLA-A NM_002116 NS - - - -3.8 NS Qiagen-NRSP8
SCAN0007.O.20 SLA Ia NM_002116 - - - -4.9 -4.6 -4.5 SLA/PRV
SCAN0032.G.07 SLA Ia NM_002116 - - - - -4.0 - SLA/PRV
SCAN0010.J.21 SLA Ia NM_002116 - - - - - -5.9 SLA/PRV
SCAA0099.O.04 SLA-7 NM_002116 - - - -3.5 -3.6 - SLA/PRV
SS00000703 PSMB8 NM_148919 NS - - 5.5 7.8 NS Qiagen-NRSP8
SCAC0037.O.09 TAP1 NM_000593 - - - - 3.9 - SLA/PRV
SS00010012 TAP1 NM_000593 - - - -7.8 NS Qiagen-NRSP8
SS00002173 TAP2 NM_000544 NS - - -6.9 - NS Qiagen-NRSP8
SS00010176 MICB NM_005931 NS - - 11.1 11.3 NS Qiagen-NRSP8
Class II antigenic 
pathway
SS00000697 HLA-DMB NM_002118 NS - - - -7.7 NS Qiagen-NRSP8
SS00000661 HLA-DOA NM_002119 NS - - - 5.2 NS Qiagen-NRSP8
SS00000973 HLA-DQA1 NM_002122 NS - - - 5.2 NS Qiagen-NRSP8
SCAB0137.B.15 HLA-DOB NM_002120 - - - -4.0 - - SLA/PRV
SCAC0044.H.08 HLA-DMB NM_002118 - - - -4.6 - - SLA/PRV
SS00000824 CIITA NM_000246 NS - - - 3.3 NS Qiagen-NRSP8
Immunity (other genes) SS00010182 CD4 NM_000616 NS - 5.1 14.6 14.1 NS Qiagen-NRSP8
SS00009986 CD69 NM_001781 NS - - -3.1 -5.9 NS Qiagen-NRSP8
SS00006217 CLEC2L XM_498242 NS - 3.2 11.8 16.1 NS Qiagen-NRSP8
SS00009653 CLEC5A NM_013252 NS - - -4.0 -6.9 NS Qiagen-NRSP8
SS00002913 IK NM_006083 NS - - - 5.0 NS Qiagen-NRSP8
SS00010183 ICAM1 NM_000201 NS - - -4.2 -9.2 NS Qiagen-NRSP8
SS00003797 IFNAR2 NM_207585 NS - - 3.5 7.9 NS Qiagen-NRSP8
SS00010797 IFNGR2 NM_005534 NS - - - -6.1 NS Qiagen-NRSP8
SS00002396 IRF1 NM_002198 NS - - -5.0 -9.3 NS Qiagen-NRSP8
SS00009562 IRF2 NM_002199 NS - - -4.4 -10.8 NS Qiagen-NRSP8
SS00000183 IRF3 NM_001571 NS - - - -3.9 NS Qiagen-NRSP8
SS00003318 IRF5 NM_032643 NS - - -3.5 -7.9 NS Qiagen-NRSP8
SS00000904 IFNA6 NM_021002 NS - - - -7.2 NS Qiagen-NRSP8
SS00010817 IFI6 NM_002038 NS - - 6.5 12.5 NS Qiagen-NRSP8
SS00010811 IFI30 NM_006332 NS - - - -6.1 NS Qiagen-NRSP8
SS00001608 ISGF3G NM_006084 NS - - - 3.9 NS Qiagen-NRSP8
SS00009843 IL12A NM_000882 NS - - -3.3 -17.1 NS Qiagen-NRSP8
SS00009841 IL12B NM_002187 NS - - -7.9 -17.1 NS Qiagen-NRSP8
SS00008021 TLR8 NM_016610 NS - - -4.6 -5.9 NS Qiagen-NRSP8
SCAA0015.B.22 PPIA NM_021130.3 - - - -3.9 -4.8 -4.8 SLA/PRV
SCAU0001.B.05 PPIA NM_021130.3 - - - -3.6 -4.3 -4.7 SLA/PRV
SS00003892 PPIL1 NM_016059 NS - - - 3.2 NS Qiagen-NRSP8
SS00001759 PPIL2 NM_148176 NS - - - 4.1 NS Qiagen-NRSP8
SS00001178 PPIF NM_005729 NS - - - -3.8 NS Qiagen-NRSP8
SS00001241 PPIG NM_004792 NS - - - -4.3 NS Qiagen-NRSP8
SS00005782 PPIH NM_006347 NS - - - 5.1 NS Qiagen-NRSP8
SS00006083 FKBP3 NM_002013 NS - - - -8.3 NS Qiagen-NRSP8
SS00002702 FKBP4 NM_002014 NS - 3.6 13.0 14.3 NS Qiagen-NRSP8
Apoptosis SS00003686 BNIP1 NM_001205 NS - - - -6.1 NS Qiagen-NRSP8
SS00000546 BAK1 NM_001188 NS - - - -4.3 NS Qiagen-NRSP8
SS00010935 BCLAF1 NM_014739 NS - -4.0 -4.6 -6.6 NS Qiagen-NRSP8
SS00001150 BCL2L1 NM_138578 NS - - -3.4 -6.5 NS Qiagen-NRSP8
SS00005026 BCL2L14 NM_138723 NS - - - -5.8 NS Qiagen-NRSP8
SS00000872 CASP1 NM_033293 NS - - 3.6 5.0 NS Qiagen-NRSP8
SS00000520 CASP3 NM_032991 NS - - - -0.7 NS Qiagen-NRSP8BMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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cell transcriptome modifications can be examined with a
unique microarray combining viral and host cell probe
sets. Indeed, a majority of transcriptomic studies have
focused either on host or on pathogen gene expression
profiling [11,22,23] and only a few studies report the
simultaneous detection of pathogen and mammalian
host transcriptomes i.e. Plasmodium berghei ANKA and
mouse [24] and EBV-NK/T cell lymphoma and man [25].
Our work confirms the feasibility and the relevance of this
kind of approach to establish a direct link between patho-
gen and cellular gene expression. In order to explore por-
cine cellular gene expression with even more detail, we
chose to supplement the SLA/PrV microarray with the
Qiagen-NRSP8 microarray. The sensitivity of each micro-
array differed according to the nature of the probes (70-
mer oligonucleotides versus DNA/cDNA) as shown by
comparative studies [26]. Seventy-mer oligonucleotides
give better results in terms of specificity and sensitivity
compared to cDNA microarrays and this could explain
some discrepancies observed between both microarrays in
particular for the TAP1 gene [27] as confirmed in our
study. With this integrated approach, a parallel increase in
the number of differentially expressed PrV and cellular
genes was detected illustrating the viral and cellular tran-
script modifications during infection.
A picture of PrV gene transcription during PK15 cell line 
infection
In our experimental conditions, we obtain a picture of the
global PrV gene transcription during the lytic cycle. PrV
transcription was monitored in single cycle conditions
using a high MOI that guarantees that more that 90% cells
are infected. Despite the presence of nested transcription
units in PrV preventing the design of probes specific of
unique transcripts for some genes, we were, however, able
to confidently report viral gene expression for probes spe-
cific of unique viral transcripts and draw a general picture
of PrV transcription during the time course of infection.
As expected, the expression of most viral genes increased
during infection. Our results show that a notable increase
in transcript levels and in the number of differentially
expressed viral probes, detected from 4 h pi, correlates
SS00004783 CASP7 NM_001227 NS - - - 6.7 NS Qiagen-NRSP8
SS00003624 CARD6 NM_032587 NS - - 3.5 6.6 NS Qiagen-NRSP8
SS00000561 DDX58 NM_014314 NS - -3.1 -4.3 -8.3 NS Qiagen-NRSP8
SS00000329 FAF1 NM_007051 NS - - - 5.8 NS Qiagen-NRSP8
SS00012494 FAIM2 NM_012306 NS - - -4.6 -10.7 NS Qiagen-NRSP8
ER* stress SS00000384 EIF2A NM_032025 NS - - 3.7 7.1 NS Qiagen-NRSP8
Pathway SS00008645 XBP1 NM_005080 NS - - - -6.4 NS Qiagen-NRSP8
SS00004223 ATF4 NM_182810 NS - - - -4.1 NS Qiagen-NRSP8
SS00001308 HSPA8 NM_006597 NS - - - 3.6 NS Qiagen-NRSP8
Nucleic acid SCAB0073.K.18 HIST1H2BK NM_080593 - - - -3.9 -6.8 -4.4 SLA/PRV
Binding SCAA0122.E.09 HIST1H2AL NM_003511 - - - -3.9 -6.0 -3.7 SLA/PRV
SCAB0057.M.21 HIST1H4J NM_021968 - - - -5.1 -4.4 -4.0 SLA/PRV
SCAB0015.G.08 HIST3H2BB NM_021968 - - - - -4.2 -5.4 SLA/PRV
SS00005067 HDAC2 NM_001527 NS - 4.6 8.3 9.1 NS Qiagen-NRSP8
SS00004784 HDAC3 NM_003883 NS - - -5.5 -10.9 NS Qiagen-NRSP8
SS00007434 HDAC6 NM_006044 NS - - -3.7 -8.4 NS Qiagen-NRSP8
SS00003586 HDAC9 NM_014707 NS - -3.5 -4.8 -10.6 NS Qiagen-NRSP8
SS00004682 HDAC10 NM_032019 NS - - - 3.9 NS Qiagen-NRSP8
SS00007084 STAT1 NM_007315 NS - - - 7.6 NS Qiagen-NRSP8
SS00008286 STAT3 NM_139276 NS - - - -4.4 NS Qiagen-NRSP8
SS00008435 STAT5B NM_012448 NS - - -5.3 -9.9 NS Qiagen-NRSP8
SS00004427 STAT6 NM_003153 NS - - - -4.6 NS Qiagen-NRSP8
Cytoskeleton SS00003440 ACTC1 NM_005159 NS - - - -8.9 NS Qiagen-NRSP8
SS00013114 ACTG1 NM_001614 NS 3.3 6.9 19.4 18.2 NS Qiagen-NRSP8
SS00002774 ACTL6A NM_004301 NS - - - 3.6 NS Qiagen-NRSP8
SS00005476 ACTRT2 NM_080431 NS - - - -7.2 NS Qiagen-NRSP8
SS00007431 ACTA4 NM_00492 NS - - -3.7 -3.9 NS Qiagen-NRSP8
SS00011046 MYO1D NM_015194 NS - - -4.7 -10.2 NS Qiagen-NRSP8
SS00007818 MYO5A NM_000259 NS - - -3.7 -9.8 NS Qiagen-NRSP8
* ER: Endoplasmic Reticulum
NS: Not Studied
-: not differentially express
Table 5: Subset of differentially expressed cellular genes at each time point. (Continued)BMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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with viral growth and thus coincides with the beginning
of the release of extracellular progeny (see Figure 2, Figure
3, Table 1 and Table 2). It has already been reported that
the beginning of viral progeny usually occurs between 4
and 5 h pi but without any description of the global viral
transcription [1]. We observe a continuous increase in
transcript levels and in the number of differentially
expressed viral probes between 4 and 8 h pi followed by a
stabilization when virion production is maximum. This
suggests that the transcriptional machinery is fully active
at 8 h pi thus permitting a massive virion production. All
the different classes of viral transcripts are represented
SLA I cell surface decrease on PrV infected PK15 cells Figure 5
SLA I cell surface decrease on PrV infected PK15 cells. Histogram overlays of MHC class I expression detected by the 
mAb PT85A are shown. The number in red represents the percent mean fluorescence intensity [(mean channel fluorescence 
of the infected sample at 8 h pi/mean channel fluorescence of the mock-infected cells at 8 h pi) × 100]. The results represent 
one of three representative experiments.
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Control
8h pi
(51.7%)
8h post-MI (100%)
0h post-MI
0h pi
Table 6: Cellular gene expression study by qRT-PCR.
Change (n-fold)
Gene MI*_T12/MI*_T0 I**_T0/MI*_T0 I*_T2/MI**_T0 I**_T4/MI*_T0 I**_T8/MI*_T0 I**_T12/MI*_T0
TNF 1.6 2.3 2.6 14.7 14.5 10.5
PPIA 1.2 1.1 0.7 0.2 0.1 0.1
SLA Ia 0.7 0.9 - - 0.6 0.5
TAP1 -- - - 0 . 8 0 . 6
TAP2 1.2 1.2 1.0 0.8 0.5 0.4
PSMB9 0.8 0.6 0.6 0.7 0.3 0.3
PSMB8 - 0.6 0.7 0.6 0.3 0.2
- - no detected difference between two samples
- *: mock-infected
- **: PrV infectedBMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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from 4 h pi (non structural, capsid, tegument and enve-
lope protein transcripts). The molecular hallmark of her-
pesvirus infection is a temporally ordered gene
transcription. As for other herpesviruses, the PrV genes are
subdivided in three main classes of successively expressed
transcripts: immediate early, early and late transcripts [1].
After binding of the viral particle and fusion of the virion
envelope with the cell membrane, the release of capsid
and tegument proteins into the cell and the takeover of
host cell protein synthesis machinery, the IE180 protein
encoded by the immediate early gene is expressed in the
cytoplasm and translocated to the nucleus. This protein
can further transactivate the RNA polymerase II mediated
transcription of early genes including transactivators of
transcription (EP0, US1, UL54) and proteins essential for
viral replication (UL5, UL8, UL9, UL29, UL30, UL42,
UL52, UL28, UL39, UL40, UL23, UL50, UL12, UL2) [1].
The expression of IE180 has been reported to begin
between 40 min and 1 h pi and last until 3 h pi [1]. In our
experiment, the IE180 probe (IEP2) was differentially
expressed only at 4 h pi, when the transcript level proba-
bly reaches its peak value. This suggests that a low level of
IE180 transcripts is sufficient to induce the transcription
of early genes. In this experiment, the differential expres-
sion of US1 and UL29 was detected as early as 1 h pi but
other early genes appeared differentially expressed later.
Interestingly, the UL49.5 probe corresponding to the gN
protein, responsible for TAP inhibition, was differentially
expressed at 1 h pi, even if this gene is not described as an
early gene. The synthesis of late proteins, such as capsid
(UL6, UL18, UL19, UL25, UL35 and UL38), tegument
(UL11, UL13, UL16, UL21, UL36, UL37, UL37, UL41,
UL46, UL47, UL48, UL49, UL51, US3, US2) and envelope
proteins (gE, gI, gD, gM, gH, gC, gB, gN, gK) are reported
to occur during the PrV replication cycle [1]. In our study,
the two late transcripts UL6 and UL22 encoding the gH
protein were differentially expressed as early as 2 h pi. The
four latest differentially expressed genes mostly encoded
envelope or tegument proteins, except UL9.
We described for the first time a global analysis of PrV
gene transcription using a microarray. The results of our
analysis is consistent with what is known about PrV viral
cycle and with the kinetic classification of individual tran-
scripts [1]. Similar approaches have been developed for
other alphaherpesviruses such as HSV-1 [28,29] and Vari-
cella-Zoster virus (VZV) [28,29]. It is difficult to compare
our results with those obtained in the VZV study because
this viral system does not allow cell infection under single
cycle synchronized conditions (one limitation of this viral
system), which is required to establish reliable kinetics of
viral gene expression. However our results are consistent
with the transcriptomic study reported for HSV-1 [28,29].
It is clear from figure 3 that PrV early homologues of HSV-
1 immediate early genes (EP0, UL54, US1) and early
genes (UL23 encoding thymidine kinase, UL30 encoding
a DNA polymerase subunit, UL39 encoding the large sub-
unit of ribonucleotide reductase) are expressed at early
times before most of the late genes encoding structural
proteins. A clear distinction between immediate early,
early and late genes for PrV will require transcriptomic
analysis in the presence of the translation inhibitor
cycloheximide (to identify immediate early genes) or the
viral DNA replication inhibitor phosphonoacetic acid (to
distinguish early and late genes) as was done for HSV-1
[28,29].
PrV and cellular shutoff
A cellular shutoff during infection has been described for
herpesviruses including PrV [1]. In our experiment, a shut-
off of PK15 genes is observed during infection since many
cellular genes are down-regulated between 4 and 12 h pi.
In contrast, at the 4 h time point, 42.5 % of the viral genes
are up-regulated. Our transcriptomic analyses reveal that
the shutoff occurs in porcine cells earlier than that previ-
ously reported in other transcriptome studies i.e. between
8 and 12 h pi in rat embryonic fibroblasts and from 6 h pi
in human embryonic kidney cells [12,14]. It is assumed
that the virion host shutoff protein (vhs/UL41 transcript)
causes cellular shutoff. The vhs protein is an RNAse
located in the viral tegument, which degrades host and
viral RNA just after infection for HSV-1 [30]. Unlike HSV-
1, it has been suggested that for cellular shutoff, PrV
requires a fresh round of viral protein synthesis explaining
the observed delayed shutoff [9]. In our experiment, UL41
transcripts appear to be differentially expressed only at 8
h pi suggesting that the vhs activity can be attributed to the
newly synthesized proteins and not to the vhs proteins
present in the virion tegument at the moment of infection
and that the vhs protein should be active at low level. The
activity of HSV-1 vhs is modulated by the UL48 product
(VP16), which can bind to vhs to allow viral mRNA accu-
mulation [31]. However, our study does not show any dif-
ferential expression of the UL48 transcript.
PrV infection and immune evasion strategies
To evade host response PrV develops several strategies that
probably disturb different biological pathways including
the MHC class I presentation pathway. We observed a
decrease of SLA-Ia and TAP2 transcript levels in PK15 cells
infected with the PrV NIA3 strain as previously reported in
infected PK15 and bovine kidney cells respectively (IND-
F PrV strain) [9]. A down-regulation of TAP1 and TAP2
genes encoding immunoproteasome catalytic subunits,
PSMB8 and PSMB9, involved in the MHC class I antigenic
presentation pathway was also detected in our experi-
ment. Moreover, we checked that at 8 h pi the PK15 cells
expressed 50% less MHC class I proteins than mock-
infected cells in our culture conditions. These results con-
firm previous reports describing the reduced capacity ofBMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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infected cells to present viral peptides to CTL [6,7]. The
viral gene UL49.5, encoding the gN protein, is one of the
earliest differentially expressed genes in our study (from 1
h pi). This viral protein has been shown to inhibit TAP
activity and induce degradation of TAP molecules by the
proteasome [5,8,32]. Our results strongly suggest a very
early production of gN protein and agree with the detec-
tion of TAP inhibition from 2 h pi [7]. This TAP inhibition
has been shown to be independent of vhs activity [9] and
we demonstrate here that UL41 encoding vhs is differen-
tially expressed later than UL49.5, indicating two succes-
sive steps i.e. TAP inhibition followed by cellular shutoff.
Since the level of several transcripts involved in the MHC
class I presentation pathway (MHC class Ia, TAP1, TAP2,
PSMB8 and PSMB9) decreased, it is possible that PrV has
developed complementary strategies to evade this path-
way i.e. turning off the peptide pump with inhibition of
TAP activity and transcription alteration of key players [5].
Other viruses, such as the human cytomegalovirus, down-
regulate the transcription of key players of the MHC class
I antigen presentation pathway [5]. Unexpectedly, some
MHC class II genes were also regulated during PrV infec-
tion in PK15 cells. In particular, a down-regulation of
class II-like chaperones SLA-DOB and SLA-DMB was
observed. MHC class II molecules that are constitutively
expressed on professional antigen presenting cells (APCs),
present peptides derived from exogenous antigens to
CD4+ T-helper cells playing an important role in the
induction and maintenance of CTL immunity. Epithelial
cells can also constitutively express MHC II molecules but
at a lower level than professional APCs [33]. In our exper-
iment, we detected a small subpopulation of uninfected
PK15 cells constitutively expressing MHC class II mole-
cules. However, we did not detect modifications of the
MHC class II expression at the cell surface. Since a down-
regulation of constitutive and IFNγ induced HLA class II
expression has been observed in cells infected by other
herpesviruses [33], our preliminary data suggest that it
would be highly relevant to explore how PrV may interfere
with the MHC class II presentation pathway in profes-
sional APCs.
In addition to genes belonging to MHC antigen presenta-
tion pathways, several other genes, playing a role in anti-
viral response are regulated during PrV infection such as
genes belonging to the IFN signaling pathway. Indeed, it
has been reported that in primary rat fibroblasts, PrV
infection could suppress the establishment of the IFNβ-
induced viral state [13]. IRF3, which is a transcriptional
factor involved in IFNβ production by epithelial cells, is
down-regulated together with a set of other IRF. Constitu-
tively expressed in the cytosol, IRF3 is phosphorylated
during herpesvirus infection and translocated into the
nucleus to target the IFNβ promoter. Many viruses inter-
fere with IRF activities [34]. A decrease of IRF1 mRNA and
protein levels has also been detected in cells infected with
hepatitis C virus, resulting in the transcriptional repres-
sion of several IFN-stimulated genes [35]. In addition,
TNF-alpha, which is a multifunctional cytokine with
potent antiviral activities and which mediates protection
against HSV-1 in the mouse [36] was analyzed by qRT-
PCR. A strong up-regulation of TNF was detected from the
beginning of PrV infection and until 12 h pi. These results
suggest that the TNF transcription increase that is usually
expected during an infection is not suppressed by PrV
infection and that the cellular shutoff does not target TNF.
Other cellular pathways modulated during PrV infection
Our transcriptome analysis confirms that many other bio-
logical processes and functions are modulated during PrV
infection in porcine PK15 cells as previously observed in
rat embryonic fibroblast and human embryonic kidney
cells [12,14]. We have focused our study on a limited
number of pathways and genes. Interestingly, we observe
both by transcriptome analysis and qRT-PCR that PPIA
gene expression is clearly down-regulated during PrV
infection. PPIA encodes cyclophilin A, a peptidyl-prolyl
isomerase, which catalyzes the isomerization of peptide
bonds from the trans to cis form at proline residues and
facilitates protein folding [37] and which acts as a
cytosolic molecular chaperone. Cyclophilins have been
discovered because of their high affinity for cyclosporine,
an immuno-suppressive drug, which prevents allograft
rejection. This immunosuppressive effect is due to the cal-
cineurin inhibition by a cyclosporin-cyclophilin complex.
Calcineurin is required for transcriptional activation of
many cytokines in stimulated T cells. Cyclophilin A can
also interact with HIV-1 Gag polyprotein and is involved
in HIV-1 replication kinetics and modifies the infectivity
of HIV-1 virions in Jurkat T cells [38]. Indeed, virions pro-
duced by PPIA-/- cells are less infectious than virions pro-
duced by PPIA+/+  cells. Since we observed a down-
regulation of PPIA before the global cellular shutoff,
cyclophilin A may be a target for PrV and play a role in
infection via an unknown mechanism.
Several cellular genes involved in apoptosis were regu-
lated during PrV infection such as BCl-2 molecules and
caspases. Viral infection of mammalian cells tends to gen-
erate proapoptotic signals to limit viral replication but
viruses and, in particular, herpesviruses produce mole-
cules acting as modulators of apoptosis [1]. Thus, US3
products from PrV play an anti-apoptotic role [39]. The
PIKNIA3 probe specific to US3 long and short isoform
transcripts was up-regulated from 8 h pi in our experi-
ment, suggesting a possible late antiapoptotic role of the
US3 products. In addition, PrV genes homologous to
other HSV-1 antiapoptotic genes may also possess an
antiapoptotic role such as UL54 or US1 [1]. UL54 was notBMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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differentially expressed in our experiment in contrast to
US1, which was up-regulated very early as soon as 1 h pi.
Genes belonging to nucleic acid metabolism were differ-
entially expressed from very early time points. A repres-
sion of many genes encoding histones and nucleosome
components occurred in PK15 cells during infection.
These results are concordant with a former study, which
has shown a gradual inhibition of histone synthesis in
RK13 rabbit cells during PrV infection [40]. We also
observed a modulation of many histone deacetylases
(HDAC). Acetylation of newly synthesized histones is
required for their assembly into nucleosomes by histone
chaperones and regulates the formation of heterochroma-
tin that is critical for cellular gene transcription. US3,
which was up-regulated from 8 h pi in our experiment,
can suppress histone acetylation during HSV1 infection
[41]. Indeed, PrV US3 could also inhibit histone acetyla-
tion during infection.
PrV infection regulates the expression of several genes
involved in actin cytoskeleton signaling. A probe specific
to ACTG1 was strongly up-regulated as soon as 1 h pi and
reached a peak at 4 h pi. Cytoskeleton actin is involved in
PrV assembly and in virus movement within the host cell.
In particular, viral capsids can travel along nuclear actin
filaments using myosin-directed transport in neurons but
also in PK15 cells [42]. Moreover, actins present in the
nucleus participate in transcription [43]. Among PrV pro-
teins, the US3 protein kinase contributes to cellular
cytoskeleton modifications via the formation of actin-
and microtubule-containing cell projections, a phenome-
non associated with an increase of PrV intercellular spread
[44].
Conclusion
The originality of our approach lies in the simultaneous
investigation of transcript levels of both host and patho-
gen genomes using a partial generic microarray and a ded-
icated microarray (SLA/PrV) combining all the PrV genes
and probes from the SLA complex. It is now necessary to
extend our analysis of the interactions between PrV and
porcine cells to other target cells, such as immature den-
dritic cells (iDC) that are the first immune cells interacting
with the virus. This kind of approach should also be effi-
cient (i) to study viral and cellular gene expression using
mutant viruses in order to better understand the role of
each viral gene and (ii) to help identify species or strain
specific transcriptomic signatures in host cells.
Methods
Cells, viruses and infection
The PK15 cells used in this study, for both viral stock pro-
duction and virus-cell interaction experiments, were prop-
agated in the H-MSM aproteic synthetic medium (R.
L'Haridon, unpublished results) without serum. This
medium consists in Eagle's Minimum Essential Medium
(EMEM) supplemented with appropriate amounts of
amino-acids, sugars, vitamins, salts and organic acids and
without any additional hormone, natural or recombinant
protein or growth factors. The PK15 cells underwent at
least 40 passages in these conditions prior to this study.
The virulent wild type NIA3 strain of Pseudorabies virus as
well as its GFP expressing derivative were grown by infect-
ing confluent PK15 cell monolayers in 175 cm2 flasks
(Corning, France) at a MOI of 0.1. After a 48 h growth
period, the cell culture medium, containing progeny viri-
ons, was collected, chilled on ice and clarified by centrifu-
gation at 4°C. Virions were purified by ion exchange
chromatography on Sartobind S cation exchanger mem-
branes (Sartorius, Palaiseau, France) as described previ-
ously [45] except that SingleSep minicapsules were used
instead of the MA100 device. After concentration by ultra-
centrifugation (Beckman SW41 rotor, 25,000 rev per min,
1 h, 4°C) purified virions were resuspended in TBSal
buffer (200 mM NaCl, 2.6 mM KCl, 10 mM Tris-HCl, pH
7.5, 20 mM MgCl2, 1.8 mM CaCl2) and stored in aliquots
at -80°C.
Infectious virus titers in purified stocks or cell culture
supernatants were determined by plaque assay on PK15
cells grown in standard conditions (EMEM containing 10
% fetal calf serum) as described previously [46].
For virus-cell interaction experiments, aliquots of PK15
cells were seeded in 50 mm Petri dishes. We used the same
batch of cells to prepare all the aliquots of the same time-
course replicate experiment. When cells reached conflu-
ence, growth medium was removed and replaced by the
inoculum (purified virions at a MOI of 20 diluted in a
small volume of fresh medium) for infection by the mock-
inoculum (virus resuspension buffer diluted the same
way) for mock-infection. After a 45 min adsorption
period at room temperature, inoculums and mock-inocu-
lums were removed and replaced, after a single rinse, by
H-MSM. At this time (considered as T0) monolayer cul-
tures were further incubated at 37°C for the time required
before RNA extraction. For flow cytometry experiments
(see below), we used the same procedure except that the
cells were mock-infected or infected with a recombinant
PrV strain (derived from the NIA3 strain) that constitu-
tively expresses the GFP under the control of the immedi-
ate-early promoter of HCMV (M. Cochet and F. Lefèvre,
unpublished data). Cells were analyzed 8 h post-infection
and we performed three replicate experiments.
RNA isolation
Cells were harvested for RNA extraction just after infection
or mock-infection (time 0), and 1, 2, 4, 8 and 12 hoursBMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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after infection or mock-infection. RNA was extracted with
the Trizol-chloroform method (Invitrogen, France), dis-
solved in 40μl DEPC treated water and quantified (Nano-
drop, nyxor Biotech). For quantitative real-time RT-PCR,
RNA was treated with DNase I and cleaned to remove any
DNA contamination (DNase set and cleanup, Qiagen,
France). RNA quality was checked on the Bioanalyzer Agi-
lent (Agilent Technologies, France) and RNA with a RIN
score between 8 and 10 were labeled and used in microar-
ray or qRT-PCR experiments. The RNA were diluted at
1μg/μl final concentration and stored at -80°C.
Design and production of the SLA/PrV microarray
The SLA/PrV microarray, composed of cDNA and sub-
cloned exons, is a dedicated array containing porcine and
PrV probes, which was produced by the CRB-GADIE
(Centre de Ressources Biologiques pour la Génomique
des Animaux Domestiques et d'Intérêt Economique,
LREG, INRA, Jouy-en Josas, France). The list of genes
present in the human SLA orthologous region (6p21-p23)
established using the human sequence draft (May 2004)
on UCSC web site [47] and porcine cDNA clones were
selected when they were available in the AGENAE library
[19] or in two American libraries MARC1PIG and
MARC2PIG constructed by the United States Department
of Agriculture (USDA). When no porcine cDNA clone was
found, exons were identified by comparison between ESTs
and genomic DNA using the ICCARE comparison map-
ping tool [48,49]. Primers were designed with Primer 3
[50].
To design the PrV amplicons, we first established a com-
plete composite sequence of the PrV genome by merging
genomic sequences available in Genbank from seven
strains of PrV. Positions of the 5' and 3' ends of viral tran-
scripts (true or putative) as well as ORFs were established
according to published data or Genbank annotations (F.
Lefèvre, unpublished). The location of the 80 amplicons,
at least one per transcript, was chosen according to this
map, generally close to the 3' end of the transcripts (Figure
1). In the case of nested transcription units, we designed
as many amplicons as the number of nested transcripts so
that each amplicon was located between the 5' ends of
two consecutive transcripts. We used Primer 3 to design
primers for amplification (30 cycles: 30 sec at 94°C, 30
sec at 60°C and 30 sec at 72°C, in the presence of 10%
DMSO). PrV probes targeting 70 viral genes [see Addi-
tional file 3] and pig exons were subcloned in PGEM-T
easy plasmid (Promega, France) and individual clones
checked for correct amplification by sequencing. For the
SLA and immune clones spotted on the SLA/PrV slides,
sequence homology was checked by multi-alignment
(BLAST) against human and pig EST databases [21,51].
The SLA/PrV microarray probes were reannotated taking
into account the most significant BLAST results and its
final geneID file was used in the analysis.
Plasmid clones bearing cDNAs, sub-cloned exons or PrV
amplicons were used as templates for preparative PCR
(Taq PCR Master Mix Kit, Qiagen, France) with universal
primers located in the vector (35 cycles, same conditions
as above for PrV amplicons and 30 sec at 94°C, 30 sec at
60°C and 2 min at 70°C for other probes). After purifica-
tion (Multiscreen-PCR plates, Millipore, France), PCR
products were checked on 1% agarose gel, quantified
using Fluoroskan Ascent (Thermo Fischer Scientific,
France), evaporated and pellets were resuspended in 13 μl
SSC3X. Forty-six control spots were added to the slide
(Lucidea Universal Scorecard, Amersham Biosciences,
France). Two identical arrays were spotted on slides (25 ×
75 mm, UltraGAPS Coated Slides, Corning) with a 16
needle spotter (Microarraywriter Pro, Virtek, France). After
spotting, slides were first treated with steam to homoge-
nize the hydration of spots. Then, spotted DNA was dena-
tured (5 sec at 100°C) and UV fixed (300 mJ). Slides were
stored in dry atmosphere before use.
The SLA/PrV DNA/cDNA microarray platform has been
submitted to the Gene Expression Omnibus (GEO) repos-
itory [52]. The accession number is GPL5622.
The generic porcine array
The second microarray is a commercial generic microarray
spotted on slides (Qiagen-NRSP8) and contains 13297
oligonucleotides (70-mers) specific of 8541 porcine genes
[17]. The microarrays used in this study were provided by
Dr Max Rothschild (Department of Animal Science, Iowa
State University). We used the annotation of Qiagen-
NRSP8 slides given by Zhao and collaborators [17].
RNA labeling, hybridization scheme, microarray scanning 
and signal quantification
Five μg of each RNA were reverse-transcribed and labeled
with Cy3 and Cy5 (reagents: Pronto kit, Corning and
Amersham, Biosciences). Labeled targets were quantified
(Nanodrop, Nyxor Biotech, France), evaporated and the
pellets were resuspended in hybridization buffer (Pronto
Kit, Corning, France) at a final concentration of 2 pmoles/
μl. Control RNA (Spikes, Lucidea Universal Scorecard,
Amersham Biosciences, France) specific to the control
spots on the SLA slides were labeled together with total
RNA.
All time points (T0, T1, T2, T4, T8 and T12 h pi) for SLA/
PrV hybridizations and only four time points for Qiagen-
NRSP8 hybridizations (T1, T2, T4 and T8 h pi) were used.
Twelve and eight different conditions were considered for
the SLA/PrV and Qiagen-NRSP8 hybridizations, respec-
tively. The hybridization scheme which can be defined asBMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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dye-switch was chosen to minimize the number of slides
used and to test the impact of several factors on the results
(conditions, labeling protocol, networks, day of experi-
mentation and samples). A balanced loop design with
two independent loops, each loop containing two repli-
cates of PrV infection and mock-infection, was used (Fig-
ure 6). In total, 24 SLA/PrV slides and 32 Qiagen-NRSP8
slides were used in this experiment. All slides were proc-
essed in the same conditions. The slides were pre-soaked,
prehybridized and hybridized with the same quantity of
Cy3 and Cy5 labeled cDNA: 20 and 40 pmoles of each
labeled cDNA for the SLA/PrV slides and for the Qiagen-
NRSP8 slides, respectively (Pronto Kit, Corning, France).
After hybridization for 16 hours at 42°C, the slides were
washed according to a commercial protocol (Pronto kit,
Corning, France) and dried by centrifugation (1500 rpm,
3 min).
SLA/PrV and Qiagen-NRSP8 slides were scanned on the
Scanarray scanner (Perkin Elmer, France) and on the
Microarrayreader scanner (Virtek, France), respectively.
Signals were quantified with the Imagene version 5.1 soft-
ware (Biodiscovery, USA). All the results were stored in
the BioArray Software Environment (BASE) of SIGENAE
(Système d'Information du projet d'Analyse des Genomes
des Animaux d'Elevage) [20].
The SLA/PrV and the Qiagen-NRSP8 microarray data have
been submitted to the GEO and received accession num-
bers GSE8676 and GSE9259, respectively.
Statistical data analysis
The normalization and statistical analysis steps were per-
formed with scripts written with R software. Functions
contained in stats, anapuce and varmixt packages were
used. Raw data were log2 transformed, normalized by
lowess (f = 0.3) and the median of each block spotted on
the slide was subtracted. Normalized data were analyzed
with a linear model. For one gene and one target, the fol-
lowing linear model was used:
Ycfnds = μc + αf + βn + δd + εs + Ecfnds
Hybridization scheme of the SLA/PrV and the Qiagen-NRSP8 microarrays Figure 6
Hybridization scheme of the SLA/PrV and the Qiagen-NRSP8 microarrays. A Hybridization scheme of the SLA/PrV 
microarrays. Forty-eight hybridizations corresponding to 24 PrV/SLA slides were hybridized (two arrays per slide, see Meth-
ods). B Hybridization scheme of the Qiagen-NRSP8 microarrays. Thirty-two Qiagen-NRSP8 slides were hybridized. Each 
labeled target is represented by its dye Cy3 or Cy5. Each arrow linking Cy3 to Cy5 represents one hybridization on one array.
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with Ycfnds = normalized intensity, μc = condition effect (1
≤ c ≤ o), αf = fluorochrome effect (1 ≤ f ≤ 2), βn = network
effect (1 ≤ n ≤ q), δd = effect of experiment day (1 ≤ d ≤ 2),
εs = sample effect (1 ≤ s ≤ r), Ecfnds = random error, o =
number of conditions, q = number of arrays, r = number
of samples. Since the effect of samples was not significant
(Student t test, p > 0.05), we did not keep it in the final lin-
ear model. Selected contrasts (defined by a linear combi-
nation of 2 or more factor level means with coefficients
that sum to zero) were tested with the Student t test:
infected condition against mock-infected condition at
each time point. The differences observed for one time
point were tested taking into account all the data for all
the time points leading to a powerful statistical test. The
false Discovery Rate (FDR) was calculated after the Stu-
dent t test (R software, varmixt package). We selected dif-
ferentially expressed genes with an FDR = 0.05.
Hierarchical clustering analysis (HCL, Eisen) was per-
formed to analyze viral genes and cellular genes that were
differentially expressed during infection (euclidian dis-
tance, average linkage) using TMeV software [53]. Aver-
ages of normalized intensities for all the mock-infected
conditions and for each infected condition were calcu-
lated and these values were centered (median) by genes.
The "k-means" method was used to identify groups of
genes with similar expression kinetics (TMeV software,
[53]). The optimal number of groups was determined by
the "Figure of Merit" method (FOM).
Functional analysis/Network and pathway analysis
The "Gene Ontology" annotations of differentially
expressed cellular genes were obtained with the Panther
software based on human orthologous genes [54]. The
biological process sub-ontology was used to classify genes
in different functional groups. The Ingenuity Pathways
Analysis (IPA) program permitted the determination of
the significant networks and the top functions associated
with the differentially expressed genes at each time point
(IPA 5.0, Ingenuity Systems Inc., USA; [55]). The IPA pro-
gram searches the Ingenuity Pathway Knowledge Base
(IPKB) for interactions (known from the literature)
between the uploaded genes and all other genes con-
tained in IPKB and generates a series of networks. The
genes selected by the IPA network analysis are called focus
genes. The Fisher exact test was used to assign statistical
significance, and each network's score is displayed as the -
log (P-value). Significant networks with a score greater
than 3 were selected (p < 0.001) and top functions associ-
ated with these networks are presented (Table 4).
Quantitative real time RT-PCR (qRT-PCR)
RNAs corresponding to mock-infected T0 and T1 and
infected T0, T2, T4, T8, T12 samples from three replicates
were used for real-time PCR analysis. Primers were chosen
with the Primer express software or manually, one of each
primer couple located on the exon-exon boundary (Table
7). Five differentially expressed porcine genes and two
other porcine genes were chosen for real-time PCR testing.
Each amplicon was sequenced and its sequence was
aligned with the gene reference sequence. Two and a half
μg of cleaned total RNA were reverse transcribed using
Superscript II enzyme (Invitrogen, France) with Oligo(dT)
primers (Invitrogen, France) and cDNAs were quantified
with the 2100 Bioanalyzer (Agilent Technologies, France)
and diluted to obtain a 30 ng/μl final concentration for all
samples. Triplicate reactions were set up in a 20μl volume
using 10 ng cDNA, PCR primers (300 nM final concentra-
tion) and SYBR Green PCR Master Mix (Applied Biosys-
tem, USA). An ABI PRISM 7900 HT sequence detection
system was used for monitoring the level of SYBR green
fluorescence. A dissociation curve was produced at the
Table 7: Sequence of primers for qRT-PCR.
Target Oligo Sequence Size(bp)
RPL32 forward TGCTCTCAGACCCCTTGTGAAG 22
reverse TTTCCGCCAGTTCCGCTTA 19
SLAIa forward CATCATTGTTGGCCTGGTTC 20
reverse CCTTTTTCACCTGAGCGC 18
TAP1 forward CCAGTATCTCAGGGATGTTGCTG 23
reverse CGCTGCTTATAGCCCCACC 19
TAP2 forward TGTTGGGTGAGACACTAATCCCTTA 25
reverse CAAAGGCATCAGGGTCAAAATC 22
PSMB9 forward GCGCTTCACCACAAATGCTA 20
reverse TCCACACCAGCAGCTGTAATG 21
PSMB8 forward TACCTGCTTGGCACCATGTCT 21
reverse AGTACAACCTGCACTCCTTGGC 22
PPIA forward GTCTCCTTCGAGCTGTTTGCA 21
reverse CCAAATCCTTTCTCCCCAGTG 21
TNF forward CCCAAGGACTCAGATCATCGTC 22
reverse AGCTGTCCCTCGGCTTTGA 19BMC Genomics 2008, 9:123 http://www.biomedcentral.com/1471-2164/9/123
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end of the cycling phase to ensure a single PCR product
and no primer dimer. Amplification efficiencies were
determined for all genes by serial dilution of cDNA using
E = 10[-1/slope]. We checked that a slope between -3.2 and -
3.5 was obtained for each primer couple to calculate the
relative expression levels of the selected genes by using the
2-ΔΔCt method. The gene encoding Ribosomal Protein L32
(RPL32) was chosen as the internal reference for each
sample. The mock-infected sample at T0 of each replicate
was used as a calibrator for all samples of one replicate.
The mean and the standard deviations for each time of
each replicate were calculated.
Flow cytometry
The anti-porcine MHC class I monoclonal antibody
(mAb) PT85A and the anti-porcine MHC class II mAb
MSA3 were purchased from VMRD (USA). The mAb
HOPC-1 (IgG2a, Beckman Coulter, USA) was used as con-
trol Ab. PE-conjugated goat Abs to mouse IgG2a were pur-
chased from Southern Biotech (USA).
PK15 cells from three kinetics replicates, either just after
mock-infection or infection with the GFP-expressing PrV
strain and 8 h after mock-infection or pi were trypsinized,
resuspended in pig serum for 20 minutes at 4°C, washed
in D-PBS and resuspended in FACS buffer. Cells were
incubated with 50μl of diluted primary antibody (1/200
in FACS Buffer) for 30 minutes at 4°C and then, after
washing, in 50 μl of diluted PE-conjugated goat anti-
mouse IgG2a (Jackson ImmunoResearch Laboratories, 1/
600 in FACS Buffer) for 30 minutes at 4°C. After two
washes in FACS Buffer, the cells were fixed in BD CellFix
(BD Biosciences, USA) solution (1/10 in sterile D-PBS)
and analyzed using a FACScalibur flow cytometer (BD
Biosciences, USA).
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